Clinical Trial Update: BromAc for Recurrent Peritoneal Mucinous Tumour or Pseudomyxoma Peritonei [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for BromAc in recurrent pseudomyxoma peritonei and peritoneal mucinous tumors; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mucinous Adenocarcinoma
• Mucinous Tumor
• Peritoneal Cancer
• Pseudomyxoma Peritonei

Drugs mentioned

• BromAc

Snippet

Sponsor: Mucpharm Pty Ltd | Conditions: Pseudomyxoma Peritonei, Peritoneal Cancer | Phase 2 | Status: UNKNOWN